Nova Eye Medical Ltd
Company Profile
Business description
Nova Eye Medical Ltd designs, develops, manufactures, markets and sells glaucoma surgical devices (GSD) for the market. Its devices are used by ophthalmic surgeons to reduce intraocular pressure (IOP) in patients with glaucoma. The company earns all its revenues from the sales of surgical devices for the treatment of glaucoma. Its AlphaRET segment is responsible for the commercialization of the 2RT ophthalmic laser; a potential treatment to delay progression to late-stage AMD for patients who have the disease in its intermediate stage. Its segments include Glaucoma Surgical Devices segment includes the design, manufacture, marketing and sale of the iTrack, iTrack Advance and the Molteno3 glaucoma surgical device; and AlphaRET.
Contact
107 Rundle Street
Kent Town
AdelaideSA5067
AUST: +61 883620193
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
301
Nova Eye Medical Ltd News & Analysis
stocks
CSL remains favourite, but biotech field broadening
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,260.90 | 40.40 | 0.44% |
| CAC 40 | 8,301.12 | 33.38 | -0.40% |
| DAX 40 | 25,968.00 | 290.11 | -1.10% |
| Dow JONES (US) | 53,115.28 | 70.62 | -0.13% |
| FTSE 100 | 10,801.98 | 22.28 | -0.21% |
| HKSE | 25,329.73 | 237.26 | -0.93% |
| NASDAQ | 26,132.60 | 238.29 | -0.90% |
| Nikkei 225 | 66,215.34 | 96.59 | -0.15% |
| NZX 50 Index | 13,786.90 | 130.40 | -0.94% |
| S&P 500 | 7,650.17 | 35.97 | -0.47% |
| S&P/ASX 200 | 9,066.70 | 41.70 | 0.46% |
| SSE Composite Index | 3,979.89 | 6.41 | -0.16% |